The American Academy of Allergy, Asthma and Immunology calls off its 2020 Annual Meeting due to coronavirus concerns

pharmafile | March 10, 2020 | News story | Medical Communications, Research and Development Big Pharma, allergy, america, asthma, immunology 

The American Academy of Allergy, Asthma and Immunology (AAAAI) has called off its 2020 Annual Meeting that was schedule to take place in March in Philadelphia.

The AAAAI leadership had been meeting on a daily basis to assess the situation based on developments that were occurring. However, based on increasing numbers of COVID-19, including the first recorded case in Philadelphia, the leadership felt that even precautions weren’t enough to protect attendees of the event.

 David M. Lang, President of the AAAAI, commenting on the cancellation, said: “Cancelling the 2020 AAAAI Annual Meeting was a difficult decision made by the AAAAI Board of Directors after careful thought and deliberation. While an incredible amount of work went into planning this year’s educational program, and all of our speakers and abstract authors have put immense time and energy into their presentations and posters, it has reached a point with COVID-19 where the AAAAI felt it was absolutely necessary to cancel the Annual Meeting in order to protect the health and safety of attendees.”

The AAAAI is an organization with more than 7,000 members in the US, Canada and 72 other countries. The members include allergists, immunologists, allied health and related healthcare professionals with an interest in allergic and immunologic diseases.

It was founded in 1943 as the American Academy of Allergy. From 1982 to 1991 it was called the American Academy of Allergy and Immunology (AAAI). Since then it has been called the AAAAI.

Conor Kavanagh

Related Content

FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment

US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s …


Asthma drug Dupixent sees positive results in child trials

Data presented at the 2021 American Thoracic Society International Conference from a Phase III trial …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content